Program Overview

Each 2-hour dinner program will be facilitated by an oncology nurse who will present key information from the Joint Analysis regarding the patient eligibility criteria, efficacy and safety data, monitoring and management of Herceptin associated toxicities.

The objectives of the program are to:

  • Describe the role of HER2 and HER2 overexpression in breast cancer.
  • Discuss key Herceptin® (trastuzumab) trial data in HER2-positive breast cancer.
  • Identify key nursing management considerations of Herceptin®-related toxicities.

Program Agenda

  • Registration/Sign-in
  • Dinner and Presentation
    • Introduction
    • Breast Cancer Overview
    • HER2 Overexpression and the Function of Herceptin® (trastuzumab)
    • Herceptin® (trastuzumab) Therapy in MBC
    • Herceptin® (trastuzumab) Therapy in the Adjuvant Setting
    • Nursing Considerations of Breast Cancer Patients Receiving Herceptin® (trastuzumab) Therapy
    • Herceptin® (trastuzumab) Overall Safety and Efficacy
  • Question and Answer Session

Please note that in accordance with Massachusetts, Vermont and Minnesota state laws, healthcare professionals licensed in these states may be prohibited from attending promotional dinner programs. Please check your state laws concerning any restrictions before registering for this program.


Date Event Location City State View Details
12/14/2010 5:30 PMHerceptin TLC Nursing Dinner ProgramThe Capital GrilleAtlantaGA View Details
11/11/2010 6:00 PMHerceptin TLC Nursing Dinner ProgramTony Angello's RistoranteNew OrleansLA View Details
11/09/2010 6:00 PMHerceptin TLC Nursing Dinner ProgramMetropolitan GrillSpringfieldMO View Details
10/28/2010 6:00 PMHerceptin TLC Nursing Dinner ProgramTarry LodgePort Chester NY View Details
10/26/2010 6:00 PMHerceptin TLC Nursing Dinner ProgramMaggiano's Little ItalyHackensackNJ View Details
10/26/2010 5:45 PMHerceptin TLC Nursing Dinner ProgramLouie's Chop HouseOak LawnIL View Details
10/26/2010 5:45 PMHerceptin TLC Nursing Dinner ProgramLouie's Chop HouseOak LawnIL View Details
10/21/2010 6:00 PMHerceptin TLC Nursing Dinner ProgramChop House MaumeeMaumeeOH View Details
10/19/2010 6:00 PMHerceptin TLC Nursing Dinner ProgramJohn Howie Steak HouseBellevueWA View Details
10/18/2010 6:00 PMHerceptin TLC Nursing Dinner ProgramAnthony's HomeportBellinghamWA View Details
10/18/2010 6:00 PMHerceptin TLC Nursing Dinner ProgramLas Brisas Southwest SteakhouseAmarilloTX View Details
10/14/2010 6:00 PMHerceptin TLC Nursing Dinner ProgramCrown SterlingLynchburgVA View Details
10/14/2010 5:30 PMHerceptin TLC Nursing Dinner ProgramNatalia'sMaconGA View Details
10/07/2010 5:00 PMHerceptin TLC Nursing Dinner ProgramThe Lodge at Wilderness RidgeLincolnNE View Details
09/23/2010 6:00 PMHerceptin TLC Nursing Dinner ProgramSolstice Kitchen & Wine BarColumbiaSC View Details
09/22/2010 5:45 PMHerceptin TLC Nursing Dinner ProgramTorreyana Grille at Hilton La JollaLa JollaCA View Details
09/22/2010 5:30 PMHerceptin TLC Nursing Dinner ProgramZia's Red Door Restaurant & Wine BarHarrisburgPA View Details
09/09/2010 6:00 PMHerceptin TLC Nursing Dinner ProgramThe Capital GrilleLas VegasNV View Details
08/18/2010 6:00 PMHerceptin TLC Nursing Dinner ProgramFlemings Prime Steak HouseEl SegundoCA View Details
08/04/2010 5:45 PMHerceptin TLC Nursing Dinner ProgramArroyo Chop HousePasadenaCA View Details

Please arrive at the program location 20 minutes prior to the start of the program to sign-in.

If you need assistance, please call our event specialists:


Telephone: (877) 282-4050

Fax: (888) 251-5650



Indications
Adjuvant indications
Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer:

  • As part of a treatment regimen containing doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
  • With docetaxel and carboplatin
  • As a single agent following multi-modality anthracycline-based therapy
Metastatic indications
Herceptin is indicated:
  • In combination with paclitaxel for the first line treatment of HER2 overexpressing metastatic breast cancer
  • As a single agent for treatment of HER2 overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease
Boxed WARNINGS and Additional Important Safety Information Herceptin administration can result in sub-clinical and clinical cardiac failure manifesting as congestive heart failure and decreased left ventricular ejection fraction. Serious infusion reactions and pulmonary toxicity have occurred; fatal infusion reactions have been reported. Exacerbation of chemotherapy-induced neutropenia has also occurred. The most common adverse reactions associated with Herceptin use were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia.

Please click here for full prescribing information for Boxed WARNINGS and additional important safety information.